Risk of clots, stroke from incorrect blood thinner dosing reduced using online dashboard

Direct oral anticoagulants are the most popular blood thinners, yet doctors commonly prescribe the wrong dose

12:17 PM

Author | Noah Fromson

prescription pad blue yellow sketch
Jacob Dwyer, Justine Ross, Michigan Medicine

Doctors and pharmacists treating people with blood thinners can reduce the rate of inappropriate dosing — as well as blood clots and strokes that can result from it — using an electronic patient management system, a study suggests.

The online dashboard, developed by the United States Veterans Health Administration in 2016, was designed to highlight and optimize the treatment of patients with direct oral anticoagulants, or DOACs, the most commonly prescribed blood thinners. 

Researchers led by Michigan Medicine used the tool to assess over 120,000 cases in which patients with atrial fibrillation or venous thromboembolism, blood clots in the veins, were treated with DOACs at 123 VA hospitals from mid-2015 through 2019. 

SEE ALSO: Popular blood thinner associated with higher risk of bleeding complications

They found that between 6.9 and 8.6% of patients received incorrect prescriptions for blood thinners. 

Adoption of the electronic DOAC patient management tool led to a decline in off-label dosing of around 8%.

The rate of blood clots and stroke also declined at every hospital that implemented the monitoring tool.

Results are published in the Journal of the American Heart Association

“While DOACs are lifesaving medications for patients with common thrombotic conditions, they can also cause serious harm when prescribed inappropriately,” said Geoffrey Barnes, M.D., M.Sc., first author and associate professor of cardiology-internal medicine at U-M Medical School.

“Not only does our study show how commonly off-label dosing of DOACs occurs, but it highlights that utilizing this DOAC population health management tool can reduce that rate of inappropriate dosing as well as downstream complications, such as stroke and clotting.”

Direct oral anticoagulants can be incorrectly prescribed up to 20% of the time. 

The two most prescribed DOACs are rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis.)

SEE ALSO: Most blood thinner dosing problems happen after initial prescription

The sites that used the system the longest demonstrated a more significant decline in inappropriate prescribing. 

In Michigan, the Michigan Anticoagulation Quality Improvement Initiative, a multi-center collaborative of statewide hospitals, built a similar dashboard using the Epic™ electronic health record. 

Five hospitals across the state currently use that system, including University of Michigan Health. 

“This study provides one of the largest and most impactful evaluations of an anticoagulation stewardship effort to show reduction in adverse clinical events,” Barnes said.

“Health systems and policymakers should consider investing in anticoagulation stewardship efforts that support pharmacists in reviewing and correcting off label direct oral anticoagulant dosing for the benefit of millions of patients who take these medications.”

Additional authors: Joshua Errickson, Ph.D., F. Jacob Seagull, Ph.D., Michael P. Dorsch, PharmD, M.S., Jeremy B. Sussman, M.D., M.S., all of University of Michigan, Charity Chen, M.S., and Rob Holleman, M.P.H., Sussman, all of the Ann Arbor VA Center for Clinical Management Research, Arthur L Allen, PharmD, CACP, of Veterans Affairs Salt Lake City Health Care System, and Patrick Spoutz, PharmD, BCPS, of Veterans Integrates Service Network 20. 

Funding/disclosures: This project was funded by the Agency for Healthcare Research and Quality (AHRQ) through grant R18HS026874.

Support for MAQI2 is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program.

Although Blue Cross Blue Shield of Michigan and MAQI2 work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.

Barnes consults for Pfizer, Bristol-Myers Squibb, Janssen, Bayer and AstraZeneca. He is on the Board of Directors for the Anticoagulation Forum. 

Paper cited: “Pharmacist Use of a Population Management Dashboard for Safe Anticoagulant Prescribing: Evaluation of a Nation-wide Implementation Effort,” Journal of the American Heart AssociationDOI: 10.1161/JAHA.124.035859

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week by subscribing to Health Lab’s two newsletters, Health & Wellness and Research & Innovation.

Sign up for the Health Lab Podcast: Add us on SpotifyApple Podcasts or wherever you get you listen to your favorite shows.


More Articles About:

Cardiovascular: Diseases & Conditions Coagulation Disorders Atrial fibrillation (Afib) Deep Vein Thrombosis (DVT) Heart disease Arrhythmia or Abnormal Heart Rhythms Cardiovascular: Preventive Cardiology Cardiac Medications Medication Interactions Pharmacy Emerging Technologies Health Care Delivery, Policy and Economics
Health Lab word mark overlaying blue cells

Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Geoff Barnes headshot

Geoffrey D Barnes, MD, MSc

Associate Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

word statin in capital letters blue and pill out of silver case
Health Lab

More than half of U.S. adults now qualify for statins under new guidelines

Cholesterol-lowering medicines called statins can reduce heart attack and stroke risk decades later; a study finds millions more people should be taking them.
A panel of five experts with a blue background and a Michigan medicine logo
Health Lab

Aortic valve replacement: Understanding TAVR and SAVR

Cardiac surgeons and interventional cardiologists discuss aortic valve replacement, including transcatheter aortic valve replacement, or TAVR, and surgical aortic valve replacement, or SAVR.
A person holds a pill near their mouth and a glass of water in the other hand, preparing to take the medication. The background is a softly focused room with shelves and blurred greenery.
Health Lab

Heart failure ‘polypill’ improves cardiac function, cuts hospitalization risk

Treatment with a “polypill” that combines multiple medications into a single daily dose significantly enhanced cardiac function and reduced hospitalizations for patients with heart failure, according to a new study.
Young boy in hospital bed smiling, wearing blue hospital gown with tigers all over it and green hospital socks
Health Lab

Expert complex heart surgery team saves baby with rare genetic heart condition

A baby boy born with a severe form of hypertrophic cardiomyopathy needed a complicated procedure few centers perform
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast

Medicare's New GLP-1 Bridge Program

An obesity expert welcomes new Medicare option for access to effective weight loss medication, and shares the new program’s limitations.
person holding scale with scrubs on and stethoscope
Health Lab

7 things to know about Medicare’s new GLP-1 coverage

Medicare coverage of GLP-1 drugs for weight loss including Wegovy and Zepbound has begun but has limits.